Biomerica(US:BMRA) Newsfilter·2025-04-23 12:19Core Insights - Biomerica, Inc. has received regulatory approval from the UAE Ministry of Health and Prevention for its Fortel® Ulcer Test, enabling the introduction of this rapid diagnostic tool for H. pylori infection in the UAE [1][5] - The Fortel® Ulcer Test is designed to detect antibodies to H. pylori, providing accurate results in just 10 minutes, which is crucial for timely medical intervention [2][8] - H. pylori infection rates are notably high in the UAE, with local studies estimating rates exceeding 50%, leading to significant health concerns including peptic ulcers and gastric cancer [3][4] Company Overview - Biomerica is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products, particularly for gastrointestinal and inflammatory diseases [7] - The company aims to improve patient outcomes through early disease detection and affordable diagnostic tools, exemplified by the Fortel® Ulcer Test [6][7] - Biomerica is expanding its presence in the Middle East, collaborating with local distributors and healthcare providers to enhance access to its diagnostic products [5][6]